Precision Without a Playbook: How Agile CDMOs Enable Personalised Drug Development

In this article, Elizabeth Hickman (CEO, AustinPx) and Dave Miller (CSO, AustinPx) discuss how as precision medicine becomes the new standard, traditional development models are falling short. This article highlights the challenges of formulating and manufacturing personalised therapies, from poor solubility and stability issues to the growing need for patient-friendly dosage forms. Agile CDMOs are stepping up to fill the gap, offering the flexibility, scientific depth and creative problem-solving needed to navigate these complex therapeutic spaces.